How has Covid affected mental health prescribing?

Clinical

How has Covid affected mental health prescribing?

In Clinical

The Covid-19 pandemic seems to have changed psychopharmaceutical prescribing patterns in England, at least in the short-term, according to data published by the NHS Business Services Authority (NHSBSA). Clinical editor Mark Greener looks at the figures

The NHS Business Services Authority examined five groups of psychopharmaceuticals:

  • Hypnotics and anxiolytics
  • Drugs used in psychoses and related disorders (‘antipsychotics’)
  • Antidepressants
  • Central nervous system (CNS) stimulants and drugs used for attention deficit hyperactivity disorder (‘CNS stimulants’)
  • Dementia drugs.

Prescribing patterns for all five changed after the Government introduced the first lockdown in March 2020. The largest monthly decrease in prescribing usually occurs in January and February, partly reflecting fewer dispensing days but, in 2020, prescribing also fell in July and August.

The number of hypnotic and anxiolytic items declined by 9.90 per cent in July and August compared with 10.1 per cent in January and February. Antipsychotics (8.94 and 9.19 per cent respectively), antidepressants (9.30 and 9.02 per cent respectively), CNS stimulants (9.34 and 8.11 per cent respectively) and dementia drugs (7.98 and 9.18 per cent respectively) also showed a dip in July and August that was similar to the fall in January and February.

The data cannot prove that Covid-19 directly changed prescribing patterns but it is a reasonable inference, in some cases at least.

The number of dementia items prescribed between March to September 2020 declined by 1.10 per cent compared with the same months in 2019 but the monthly average number of patients receiving at least one dementia drug increased by 0.79 per cent compared with 2019.

The NHSBSA suggests that the decrease in items and increase in patients may reflect the issuing of longer prescriptions to help shield older people. 

Yearly comparison 

The NHSBSA went on to explore the pandemic’s impact by comparing prescribing between March and September 2020 with the same months in 2019. The number of hypnotics and anxiolytics prescribed between March and September 2020 declined by 2.32 per cent compared with 2019.

However, antidepressant prescribing increased by 4.81 per cent compared with the same months in 2019, while the number of antipsychotic items also increased by 3.97 per cent. 

Long-term trends

These changes occur against the backdrop of long-term trends, which makes disentangling any specific Covid-19 effect difficult. For instance, healthcare professionals issued 19.6 million antidepressant prescription items between July and September 2020 – up 2 per cent compared with April to June 2020 and 4 per cent compared with July and September 2019.

Indeed, antidepressant prescribing rose by 29.9 per cent, an increase of 4.22 million items per quarter, between July and September 2015 and the same quarter in 2020.

The number of patients prescribed one or more antipsychotic increased by 3.37 per cent from the same quarter in 2019 but fell by 1.81 per cent from the previous quarter in 2020 (possibly due to the difficulties monitoring people during lockdown). Nevertheless, the overall trend remains up: the number of patients and items rose by 16.2 and 18.9 per cent since July and September 2015.

Prescribing of dementia drugs, and hypnotics and anxiolytics all declined. The 1 million items prescribed for dementia between July and September 2020 represents a 3 per cent decline compared with the previous quarter of 2020 and a 5 per cent fall compared with the same quarter in 2019. The 3.54 million hypnotics and anxiolytics prescribed between July and September 2020 represents a 3.26 per cent decrease compared with 2019, while healthcare professionals have been prescribing 464,000 fewer hypnotic and anxiolytic items a quarter since 2015/16.

The pandemic has probably produced a short-term effect on pyschopharmaceutical prescribing, but the March to September 2020 data suggest a limited impact on long-term trajectories.

Record my learning outcomes

Clinical

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Clinical

Briefing: a novel approach to treating depression

Could a headset that delivers transcranial direct-current stimulation be the next big thing in treating depression?

6 Min Article

bookmark_icon_off
Clinical

One in eight: Young people and mental health

Over 12 per cent of five to 19-year-olds are currently dealing with at least one mental health disorder.

20 Min Article

bookmark_icon_off
Clinical

Venous leg ulcers: A silent crisis?

Described as ‘a silent crisis’ in a recent report published by the All-Party Parliamentary Group on Vascular and Venous Disease (VVAPPG), venous leg ulcers impose a heavy burden on both sufferers and the healthcare system as a whole.

16 Min Article

bookmark_icon_off
Clinical

Growing pains

Feeling comfortable in your own skin can be a challenge at any age but for today’s adolescents, social media is making things a lot more complicated when it comes to their health.

18 Min Article

bookmark_icon_off
Clinical

How pharmacy can support young parents

Supporting young parents can be the beginning of an enduring relationship between pharmacy and customer.
 

14 Min Article

bookmark_icon_off
Clinical

When the drugs don't work

As the evidence stacks up against the use of opioids for chronic pain, there’s a clear role for community pharmacists in helping people.

16 Min Article

Recommended Learning

bookmark_icon_off
Sponsored Education

Challenge your thinking on warts and verrucas

Discover different treatment options for warts and verruas and when to recommend them to your customers, based on their individual needs

20 Min Module

bookmark_icon_off
Sponsored Education

Update your knowledge of erection problems with key learning updates from recent research

4 Min Module

bookmark_icon_off
Sponsored Education

Helping customers treat & care for their scalp

Understanding the causes and symptoms of some common scalp conditions will help you to make a real difference to your customers’ lives. Complete this module to discover self-care and product advice to help ease symptoms and maintain scalp health.

24 Min Module

bookmark_icon_off
Sponsored Education

Understanding the impact of dry skin conditions

Learn about the emotional impact of dry and eczema-prone skin, and confidently recommend products for skin treatment and maintenance.

15 Min Module

bookmark_icon_off
Sponsored Education

Advising on stimulant laxatives

Find out how new MHRA regulations affect the supply of stimulant laxatives so you can reassure customers and help them find the right products

15 Min Module

bookmark_icon_off
Sponsored Education

Advising on back pain

This module highlights topical therapy options and 5 simple S.T.E.P.S. to help customers manage and prevent back pain

26 Min Module